Dimerix Limited
Dimerix Limited
Your view on DXB.AX
Overview
What the company does, where it operates, and who runs it.
About Dimerix Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Nina Webster
- Headquarters
- 425 Smith Street, Fitzroy, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Nina Webster
- Headquarters
- 425 Smith Street, Fitzroy, VIC, AU
Dimerix Limited is an Australian biopharmaceutical firm dedicated to discovering and bringing to market innovative pharmaceutical solutions for medical conditions where existing treatments are insufficient.
The company's leading therapeutic candidate, DMX-200, is currently undergoing extensive clinical evaluation, including two separate Phase 3 trials targeting respiratory complications linked to COVID-19.
DMX-200 is also in a distinct Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS), a severe kidney disorder, and is being developed for the treatment of diabetic kidney disease. Additionally, Dimerix is advancing DMX-700, which is intended for chronic obstructive pulmonary disease (COPD).
The company's corporate headquarters are located in Fitzroy, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Dimerix Limited. Starting points for Dimerix Limited: EPS -AUD 0.05, beta 0.34 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Dimerix Limited. Dimerix Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Dimerix Limited. Trailing twelve-month EPS for Dimerix Limited stands at -AUD 0.05. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterDec 2026 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|
| Average estimate | AUD 0.00 | −AUD 0.04 | −AUD 0.03 |
| Lowest estimate | AUD 0.00 | −AUD 0.04 | −AUD 0.03 |
| Highest estimate | AUD 0.00 | −AUD 0.04 | −AUD 0.03 |
| Number of analysts | 0 | 1 | 1 |
| A year ago | — | −AUD 0.05 | — |
| Growth vs a year ago | — | +23.5% | — |
Revenue estimates
| Total | This quarterDec 2026 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|
| Average estimate | AUD 2.74M | AUD 9.10M | AUD 21.50M |
| Lowest estimate | AUD 2.74M | AUD 9.10M | AUD 21.50M |
| Highest estimate | AUD 2.74M | AUD 9.10M | AUD 21.50M |
| Number of analysts | 1 | 1 | 1 |
| A year ago | — | AUD 4.35M | — |
| Growth vs a year ago | — | +109.2% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Dimerix Limited. Dimerix Limited has reported as a listed company since 1989. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| ACW.AXActinogen Medical Limited | Healthcare | Biotechnology | — | ||
| ATH.AXAlterity Therapeutics Limited | Healthcare | Biotechnology | — | ||
| ATX.AXAmplia Therapeutics Limited | Healthcare | Biotechnology | — | ||
| ILA.AXIsland Pharmaceuticals Limited | Healthcare | Biotechnology | — | ||
| NOX.AXNoxopharm Limited | Healthcare | Biotechnology | — | ||
| NYR.AXNyrada Inc. | Healthcare | Biotechnology | — | ||
| PTX.AXPrescient Therapeutics Limited | Healthcare | Biotechnology | — | ||
| RAC.AXRace Oncology Limited | Healthcare | Biotechnology | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PTGXProtagonist Therapeutics, Inc. | Healthcare | NASDAQ | $8.3B | ||
| PTHSPelthos Therapeutics Inc. | Healthcare | AMEX | $27.9M | ||
| PTIXProtagenic Therapeutics, Inc. | Healthcare | NASDAQ | $470,654 | ||
| PTNPalatin Technologies, Inc. | Healthcare | NASDAQ | $9.2M | ||
| PULMPulmatrix, Inc. | Healthcare | NASDAQ | $4.9M | ||
| PVCTProvectus Biopharmaceuticals, Inc. | Healthcare | OTC | $18.7M | ||
| PVLAPalvella Therapeutics, Inc. | Healthcare | NASDAQ | $2.1B | ||
| PXMDPaxMedica, Inc. Common Stock | Healthcare | OTC | $37,879 | ||
| PXXLFPoxel S.A. | Healthcare | OTC | $13.4M | ||
| PYC.AXPYC Therapeutics Limited | Healthcare | ASX | — | ||
| OBXObsidian Therapeutics Inc. | Healthcare | NASDAQ | $12.7M | ||

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Dimerix Limited.